PURPOSE: At the end of the 1970s it was thought that advanced epithelial ovarian cancer (EOC) could be cured by multimodality treatment using surgery, cisplatin-based combination chemotherapy, and radiotherapy (RT). Such multimodality treatment was used as standard therapy at our institution. Our long-term results are reviewed. PATIENTS AND METHODS: One hundred ninety-five previously untreated patients with stage III or IV EOC were treated between April 1979 and December 1982. All patients were to have debulking surgery, when feasible, followed by the administration of doxorubicin and cisplatin at 50 mg/m2 every 3 weeks until a total dose of doxorubicin of 450 mg/m2 had been reached. RT was used in addition in patients with disease remaining after the chemotherapy. Maintenance chemotherapy with oral cyclophosphamide and hexamethylmelamine (altretamine) was administered to patients who did not have a documented histologic complete remission. RESULTS: The 10-year overall and failure-free survivals were 4% and 8%, respectively. The median overall survival was 2 years. The achievement of a histologic complete response (n = 32) did not equate to cure because 20 (63%) of the patients eventually relapsed. Multivariate analysis identified residual disease of greater or less than 2 cm as the only independent prognostic factor. CONCLUSIONS: Our multimodality treatment program was noncurative for the majority of the patients. Innovative therapies are needed before we can hope to cure such disease.
PURPOSE: At the end of the 1970s it was thought that advanced epithelial ovarian cancer (EOC) could be cured by multimodality treatment using surgery, cisplatin-based combination chemotherapy, and radiotherapy (RT). Such multimodality treatment was used as standard therapy at our institution. Our long-term results are reviewed. PATIENTS AND METHODS: One hundred ninety-five previously untreated patients with stage III or IV EOC were treated between April 1979 and December 1982. All patients were to have debulking surgery, when feasible, followed by the administration of doxorubicin and cisplatin at 50 mg/m2 every 3 weeks until a total dose of doxorubicin of 450 mg/m2 had been reached. RT was used in addition in patients with disease remaining after the chemotherapy. Maintenance chemotherapy with oral cyclophosphamide and hexamethylmelamine (altretamine) was administered to patients who did not have a documented histologic complete remission. RESULTS: The 10-year overall and failure-free survivals were 4% and 8%, respectively. The median overall survival was 2 years. The achievement of a histologic complete response (n = 32) did not equate to cure because 20 (63%) of the patients eventually relapsed. Multivariate analysis identified residual disease of greater or less than 2 cm as the only independent prognostic factor. CONCLUSIONS: Our multimodality treatment program was noncurative for the majority of the patients. Innovative therapies are needed before we can hope to cure such disease.
Authors: Brooke L Fridley; Gregory D Jenkins; Ya-Yu Tsai; Honglin Song; Kelly L Bolton; David Fenstermacher; Jonathan Tyrer; Susan J Ramus; Julie M Cunningham; Robert A Vierkant; Zhihua Chen; Y Ann Chen; Ed Iversen; Usha Menon; Aleksandra Gentry-Maharaj; Joellen Schildkraut; Rebecca Sutphen; Simon A Gayther; Lynn C Hartmann; Paul D P Pharoah; Thomas A Sellers; Ellen L Goode Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-02 Impact factor: 4.254
Authors: Brooke L Fridley; Prabhakar Chalise; Ya-Yu Tsai; Zhifu Sun; Robert A Vierkant; Melissa C Larson; Julie M Cunningham; Edwin S Iversen; David Fenstermacher; Jill Barnholtz-Sloan; Yan Asmann; Harvey A Risch; Joellen M Schildkraut; Catherine M Phelan; Rebecca Sutphen; Thomas A Sellers; Ellen L Goode Journal: Front Genet Date: 2012-08-08 Impact factor: 4.599